Name | Number of supported studies | Average coverage | |
---|---|---|---|
cardiac muscle cell | 5 studies | 31% ± 7% | |
epithelial cell | 5 studies | 33% ± 17% | |
type I pneumocyte | 5 studies | 26% ± 6% | |
glutamatergic neuron | 3 studies | 24% ± 2% | |
basal cell | 3 studies | 37% ± 19% | |
transit amplifying cell | 3 studies | 37% ± 26% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 18% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 82% | 2018.18 | 270 / 328 | 87% | 16.29 | 155 / 178 |
stomach | 74% | 3341.67 | 267 / 359 | 94% | 19.13 | 270 / 286 |
intestine | 41% | 1719.31 | 396 / 966 | 98% | 21.66 | 515 / 527 |
thymus | 63% | 1021.77 | 414 / 653 | 74% | 6.36 | 446 / 605 |
esophagus | 39% | 2796.52 | 562 / 1445 | 96% | 26.66 | 176 / 183 |
liver | 42% | 625.40 | 94 / 226 | 66% | 5.57 | 266 / 406 |
tonsil | 0% | 0 | 0 / 0 | 98% | 31.45 | 44 / 45 |
heart | 97% | 11339.25 | 839 / 861 | 0% | 0 | 0 / 0 |
muscle | 93% | 4952.47 | 743 / 803 | 0% | 0 | 0 / 0 |
lung | 18% | 273.16 | 102 / 578 | 75% | 11.05 | 862 / 1155 |
prostate | 22% | 356.90 | 54 / 245 | 62% | 3.95 | 311 / 502 |
skin | 72% | 8429.93 | 1304 / 1809 | 9% | 0.86 | 42 / 472 |
uterus | 2% | 83.88 | 4 / 170 | 76% | 15.99 | 351 / 459 |
breast | 25% | 411.08 | 116 / 459 | 40% | 2.53 | 443 / 1118 |
ovary | 0% | 0 | 0 / 180 | 61% | 5.00 | 261 / 430 |
bladder | 0% | 0 | 0 / 21 | 57% | 8.80 | 288 / 504 |
kidney | 0% | 0 | 0 / 89 | 36% | 2.35 | 326 / 901 |
brain | 13% | 266.55 | 332 / 2642 | 0% | 0.02 | 3 / 705 |
blood vessel | 8% | 141.22 | 111 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 0% | 0 | 0 / 258 | 3% | 0.15 | 8 / 230 |
adipose | 2% | 35.05 | 26 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 1.36 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0032436 | Biological process | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0016567 | Biological process | protein ubiquitination |
GO_0031397 | Biological process | negative regulation of protein ubiquitination |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0046329 | Biological process | negative regulation of JNK cascade |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004864 | Molecular function | protein phosphatase inhibitor activity |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0019902 | Molecular function | phosphatase binding |
GO_0008157 | Molecular function | protein phosphatase 1 binding |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | SH3RF2 |
Protein name | E3 ubiquitin-protein ligase SH3RF2 (EC 2.3.2.27) (Heart protein phosphatase 1-binding protein) (HEPP1) (POSH-eliminating RING protein) (Protein phosphatase 1 regulatory subunit 39) (RING finger protein 158) (RING-type E3 ubiquitin transferase SH3RF2) (SH3 domain-containing RING finger protein 2) SH3 domain containing ring finger 2 |
Synonyms | POSH3 RNF158 PPP1R39 POSHER |
Description | FUNCTION: Has E3 ubiquitin-protein ligase activity . Acts as an anti-apoptotic regulator of the JNK pathway by ubiquitinating and promoting the degradation of SH3RF1, a scaffold protein that is required for pro-apoptotic JNK activation . Facilitates TNF-alpha-mediated recruitment of adapter proteins TRADD and RIPK1 to TNFRSF1A and regulates PAK4 protein stability via inhibition of its ubiquitin-mediated proteasomal degradation . Inhibits PPP1CA phosphatase activity . . |
Accessions | Q08AM8 ENST00000359120.9 [Q8TEC5-1] ENST00000511217.1 [Q8TEC5-1] Q8TEC5 |